Dimensional Fund Advisors LP lifted its stake in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 5.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 593,310 shares of the biotechnology company’s stock after purchasing an additional 32,640 shares during the quarter. Dimensional Fund Advisors LP owned about 3.10% of Enanta Pharmaceuticals worth $48,005,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of ENTA. Farallon Capital Management LLC grew its stake in shares of Enanta Pharmaceuticals by 124.3% during the 4th quarter. Farallon Capital Management LLC now owns 925,000 shares of the biotechnology company’s stock worth $54,279,000 after purchasing an additional 512,667 shares during the period. Matarin Capital Management LLC acquired a new stake in Enanta Pharmaceuticals in the 1st quarter valued at about $18,084,000. Millennium Management LLC acquired a new stake in Enanta Pharmaceuticals in the 4th quarter valued at about $12,959,000. Prudential Financial Inc. grew its stake in Enanta Pharmaceuticals by 134.2% in the 1st quarter. Prudential Financial Inc. now owns 217,190 shares of the biotechnology company’s stock valued at $17,573,000 after acquiring an additional 124,458 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in Enanta Pharmaceuticals by 58.9% in the 4th quarter. Franklin Resources Inc. now owns 317,700 shares of the biotechnology company’s stock valued at $18,643,000 after acquiring an additional 117,700 shares during the last quarter. 76.21% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts recently commented on ENTA shares. ValuEngine raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. BidaskClub raised shares of Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 14th. Royal Bank of Canada reissued a “hold” rating and issued a $80.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, April 4th. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 10th. Finally, Oppenheimer started coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, May 24th. They issued a “buy” rating and a $135.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Enanta Pharmaceuticals has an average rating of “Buy” and a consensus price target of $83.71.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Tuesday, May 8th. The biotechnology company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.08. The company had revenue of $44.00 million for the quarter, compared to analyst estimates of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. The firm’s quarterly revenue was up 388.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.28) EPS. equities research analysts predict that Enanta Pharmaceuticals Inc will post 3.36 earnings per share for the current year.
In other Enanta Pharmaceuticals news, Treasurer Paul J. Mellett sold 15,000 shares of the company’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $120.57, for a total value of $1,808,550.00. Following the transaction, the treasurer now directly owns 88,158 shares in the company, valued at approximately $10,629,210.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Nathalie Adda sold 4,155 shares of the company’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $114.85, for a total transaction of $477,201.75. Following the completion of the transaction, the vice president now owns 7,755 shares in the company, valued at $890,661.75. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 52,535 shares of company stock worth $5,730,391. 10.56% of the stock is owned by insiders.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.